Abstract :
I read with great interest the paper by Taheri et al. published
in (1) Hepatitis Monthly (Number 31, February
2011). The results of this follow-up study are hopeful of
hepatitis-B vaccine efficacy in patients who lost HBsAg
and did not seroconvert to anti-HBs with no detectable
HBV DNA. However, the editorial in the same issue, as
well as Taheri et al. themselves, noted some important
limitations to this study (2).
